Aberdeen Group plc Sells 824,353 Shares of Zoetis Inc. $ZTS

Zoetis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group slashed its Zoetis stake by 89.6% in the third quarter, selling 824,353 shares and retaining 95,470 shares valued at about $6.7 million.
  • Zoetis reported quarterly EPS of $1.75, beating the $1.51 consensus, and revenue of $2.39 billion, above estimates; revenue nevertheless fell 1.3% year over year.
  • Analysts’ consensus rating was Hold, with an average price target of $101.25. Zoetis also declared a quarterly dividend of $0.53 per share.
  • Five stocks to consider instead of Zoetis.

Aberdeen Group plc cut its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 89.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,470 shares of the company's stock after selling 824,353 shares during the quarter. Aberdeen Group plc's holdings in Zoetis were worth $6,667,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Flossbach Von Storch SE purchased a new stake in shares of Zoetis during the 2nd quarter valued at about $302,601,000. BlackRock Inc. lifted its position in Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new position in Zoetis in the 1st quarter worth approximately $286,660,000. Southpoint Capital Advisors LP boosted its holdings in Zoetis by 340.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company's stock worth $260,062,000 after acquiring an additional 1,700,000 shares during the period. Finally, Carmignac Gestion purchased a new position in Zoetis in the 2nd quarter worth approximately $113,230,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Down 5.5%

ZTS stock opened at $80.85 on Friday. The firm has a market cap of $32.85 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 1.24 and a beta of 0.67. Zoetis Inc. has a 1-year low of $68.77 and a 1-year high of $132.49. The firm has a fifty day moving average price of $77.04 and a two-hundred day moving average price of $90.76. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating the consensus estimate of $1.51 by $0.24. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The company's quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.70 EPS. Research analysts predict that Zoetis Inc. will post 6.29 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis's dividend payout ratio is presently 36.05%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ZTS. Stifel Nicolaus dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a research note on Thursday, August 20th. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, August 7th. William Blair lowered shares of Zoetis from an "outperform" rating to a "market perform" rating in a report on Thursday, August 6th. BNP Paribas Exane dropped their price target on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group boosted their price objective on shares of Zoetis from $83.00 to $85.00 in a report on Friday, November 6th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $101.25.

Read Our Latest Stock Report on Zoetis

Latest Zoetis News

Here's some of the latest news about ZTS:

About Zoetis

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company's offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Featured Articles

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zoetis Right Now?

Before you consider Zoetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.

While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines